PCSA Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
3.3M
-10.0%
3.7M
+6.1%
3.5M
-11.7%
4.0M
+38.8%
2.8M
R&D
1.8M
-14.4%
2.1M
+27.2%
1.7M
-32.1%
2.4M
+54.1%
1.6M
SG&A
1.5M
-4.2%
1.6M
-13.1%
1.8M
+21.5%
1.5M
+19.5%
1.3M
Operating Income
-3331214
+10.0%
-3701889
-6.1%
-3488843
+11.7%
-3950783
-38.8%
-2846990
EBITDA
-3330913
+10.0%
-3701588
-6.1%
-3488542
+11.7%
-3950482
-38.8%
-2846689
Net Income
-3377179
-0.5%
-3358938
+2.3%
-3436573
+12.6%
-3933918
-38.8%
-2834405
EPS (Basic)
$-1.29
+10.4%
$-1.44
+17.7%
$-1.75
+72.0%
$-6.25
+17.5%
$-7.58
EPS (Diluted)
$-1.29
+10.4%
$-1.44
+17.7%
$-1.75
+72.0%
$-6.25
+17.5%
$-7.58
Shares (Diluted)
2.6M
+12.1%
2.3M
+23.1%
1.9M
+205.3%
622.8K
+66.5%
374.0K
Processa Pharmaceuticals, Inc. Common (PCSA) โ€” Financials